mitoxantrone has been researched along with Peritonitis in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 6.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies." | 2.67 | Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994) |
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 2.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone (MXN) has demonstrated therapeutic efficacy in the intraperitoneal treatment of malignancies." | 1.30 | Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone. ( Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H; Wölfl, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oza, AM | 1 |
| ten Bokkel Huinink, W | 1 |
| Dubbelman, R | 1 |
| Soepenberg, O | 1 |
| Mandjes, I | 1 |
| Aartsen, E | 1 |
| McVie, JG | 1 |
| Dufour, P | 1 |
| Bergerat, JP | 1 |
| Barats, JC | 1 |
| Giron, C | 1 |
| Duclos, B | 1 |
| Dellenbach, P | 1 |
| Ritter, J | 1 |
| Renaud, R | 1 |
| Audhuy, B | 1 |
| Oberling, F | 1 |
| Tarraza, HM | 1 |
| Boyce, CR | 1 |
| Smith, WG | 1 |
| Jones, MA | 1 |
| Luftensteiner, CP | 1 |
| Schwendenwein, I | 1 |
| Eichler, HG | 1 |
| Paul, B | 1 |
| Wölfl, G | 1 |
| Viernstein, H | 1 |
2 trials available for mitoxantrone and Peritonitis
| Article | Year |
|---|---|
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito | 1994 |
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
2 other studies available for mitoxantrone and Peritonitis
| Article | Year |
|---|---|
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter | 1993 |
Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Eating; Female; Humans; Injections, I | 1999 |